Rheumatoid Arthritis: Primary Care Initiative for Improved Diagnosis and Outcomes
1.00 AMA PRA Category 1 Credits™, 1.00 AANP, 1.00 ANCC
Learning Objective
- Correctly identify patients who have probable early RA and should be referred to a rheumatologist
- Employ the “squeeze test” to assist with diagnosis of RA
- Evaluate patients by using functional assessment questions when RA is suspected
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 1.00 |
AMA PRA Category 1 Credits™ |
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
pmiCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| 1.00 |
AANP |
pmiCME is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308. |
This program has been approved for 1 contact hours of continuing education, which includes .5 hours of pharmacology. |
| 1.00 |
ANCC |
pmiCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. |
This activity for 1 contact hours is provided by pmiCME. |
Faculty and Editorial Board
Written By:
Lin A. Brown, MD, (Read Bio), Associate Professor of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Paul P. Doghramji, MD, FAAFP, (Read Bio), Family Physician, Collegeville Family Practice, Medical Director of Health Services, Ursinus College, Collegeville, Pennsylvania
David S. Kountz, MD, MBA, FACP, (Read Bio), Associate Professor of Medicine, Robert Wood Johnson Medical School, New Brunswick, New Journal
Arthur Weinstein, MD, FACP, MACR, (Read Bio), Associate Chairman, Department of Medicine, Director, Division of Rheumatology, Washington Hospital Center, Professor of Medicine, Georgetown University Medical Center, Washington, DC
Yusuf Yazici, MD, (Read Bio), Assistant Professor of Medicine, New York University School of Medicine, Director, Seligman Center for Advanced Therapeutics,Director, Behcet’s Syndrome Evaluation Treatment and Research Center, New York University Hospital for Joint Disease
Reviewed By:
Michael E. Weinblatt, MD, John R. and Eileen K. Riedman Professor of Medicine, Harvard Medical School, Co-Director, Clinical Rheumatology, Brigham and Women's Hospital, Boston, MA
Edited By:
Zachary Schwartz, MSc, ELS, pmiCME
Financial Disclosure Statement(s)
Dr Brown has no financial relationships to disclose.
Dr Doghramji is on speakers bureaus for Cephalon, Inc; Pfizer Inc; sanofi-aventis US LLC; and Takeda Pharmaceuticals North America, Inc; and advisory boards for Cephalon, Inc.
Dr Kountz is on speaker bureaus for Novartis Pharmaceuticals Corporation; advisory boards for Daiichi-Sankyo, Inc.; Forest Laboratories, Inc.; NiCox; Novartis Pharmaceuticals Corporation; and sanofi-aventis US LLC; and receives honoraria from AstraZeneca Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc, and sanofi-aventis U.S. LLC.
Dr Weinstein is a consultant for GlaxoSmithKline and Human Genome Sciences and receives research grants from Genentech, Inc.; GlaxoSmithKline; Human Genome Sciences; Pfizer, Inc; Rigel; UCB Pharma, Inc.; and XDx.
Dr Yazici is a consultant for Bristol-Myers Squibb, Centocor, Pfizer, and Roche; is on speakers bureaus for Bristol-Myers Squibb and Pfizer; and receives research grants from Genentech, Bristol-Myers Squibb, Pfizer, and Roche.
Dr Weinblatt receives consulting fees or research funding from Abbott Laboratories, Alza Corporation, Amgen Inc., Arthritis Foundation, AstraZeneca Pharmaceuticals, Bioassets Development Corporation, Biogen Idec, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd., Celgene Corporation, Centocor, Inc., Critical Therapeutics, Inc., Eli Lilly and Company, EntreMed, Inc., F. Hoffman-La Roche, Ltd, Genentech, Inc., Gilead, Human Genome Sciences, Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, Praecis Pharmaceuticals,Proprius Pharmaceuticals, Inc., Rigel, sanofi-aventis U.S. LLC, Scios, Inc., Serono Pharmaceutical Company, Synta Pharmaceuticals Corp., Trubion Pharmaceuticals Inc., VBL, Wyeth Pharmaceuticals.
The content collaborators at Chatham Institute have no financial relationships to disclose.
Mr Schwartz has no financial relationships to disclose.
Commercial Support:
Abbott Laboratories, Bristol-Myers Squibb Company, Centocor, Inc., Genentech, Inc. and Biogen Idec
|
